Fungal infections kill an estimated 1.5 million people globally each year; yet, they are not widely-recognized and are equally as dangerous as bacterial and viral infections. With the rise in resistance to first and second line antifungal therapies, the lack of awareness and distinction in the industry and general public is troublesome. Additionally, the burden of drug-resistant fungal infections carries substantial morbidity and mortality and are a costly, common problem in healthcare settings. There is an urgent and dire need for therapeutic stewardship to reduce resistance as well as for innovation in research and development for new and differentiated therapies. This panel will focus on the growing global public health epidemic and highlight the urgent needs and opportunities in the space. Particularly, attendees can expect to hear insight on the current scientific innovations, how they differ from the current class of antifungals on the market and the challenges of resistant antifungals.
Session ID: 22252